双氢青蒿素纳米结构脂质载体抗肿瘤作用的研究

Antitumor effects of the nanostructured lipid carriers of dihydroartemisinin

目的:考察双氢青蒿素纳米结构脂质载体(DHA-NLC)的体内外抗肿瘤活性。方法:以抑瘤率为指标,比较DHA-NLC与双氢青蒿素混悬液对荷瘤小鼠实体瘤生长的抑制作用。MTT法检测DHA-NLC对人白血病细胞K562、人白血病多药耐药细胞株K562/ADM(KA)及神经胶质瘤细胞U87的增殖活性。结果:DHA-NLC高、中、低剂量组的抑瘤率分别为74.43%,81.13%和88.70%,同等剂量下的双氢青蒿素普通混悬液的抑瘤率分别为64.93%,74.55%和82.37%;DHA-NLC对K562,KA及U87细胞的增殖具有明显的抑制效应,与浓度和时间呈正相关(P<0.05)。同浓度的DHA-NLC对K562细胞、KA细胞及U87细胞的增殖抑制作用明显高于双氢青蒿素普通混悬液。结论:DHA-NLC具有显著的抗肿瘤作用。

Objective： To investigate the in vivo and in vitro antitumor activity of nanostructured lipid carriers of dihydroartemisinin（DHA-NLC）.Methods： The inhibition effects of DHA-NLC and DHA suspension on solid tumor growth were evaluated in tumor-bearing mice with evaluation criterion of the inhibition rate.MTT assay was used to detect proliferation activity on human leukemia cells（K562）,human leukemia multidrug resistance cell line K562 / ADM（KA） and glioma cells（U87）.Results： DHA-NLC significantly inhibited tumor growth at 20,40 and 80 mg·kg-1,and the inhibition rates were 74.43%,81.13%,88.70% and 64.93,74.55,and 82.37%,respectively.DHA-NLC obviously inhibited cell proliferation in K562,KA and U87 cells,which was positively related to the time and concentration（P 0.05）.Inhibition rates of DHA-NLC on proliferation of K562KA and U87 cells were significantly higher than those of dihydroartemisinin ordinary suspension at the same concentration.Conclusion： DHA-NLC has significant antitumor effect.